



Original Articles

Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer

Caroline Kreuzinger^{a,1}, Isabel von der Decken^{a,1}, Andrea Wolf^a, Magdalena Gamperl^a, Julia Koller^a, Jasmine Karacs^a, Stephanie Pfaffinger^a, Thomas Bartl^a, Alexander Reinthaller^a, Christoph Grimm^a, Christian F. Singer^b, Elena Ioana Braicu^{c,d}, Paula Cunnea^e, Charlie Gourley^f, Dominiek Smeets^{g,h}, Bram Boeckx^{g,h}, Diether Lambrechts^{g,h}, Paul Perco^{i,2}, Reinhard Horvat^j, Els M.J.J. Berns^k, Dan Cacsire Castillo-Tong^{a,*}

^a Translational Gynecology Group, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, 1090, Vienna, Austria

^b Department of Gynecology and Gynecologic Oncology, Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, 1090, Vienna, Austria

^c Tumor Bank Ovarian Cancer Network, Department of Gynecology, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany

^d Department of Gynecology, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany

^e Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, W12 0HS, United Kingdom

^f Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XR, United Kingdom

^g KU Leuven, Department of Human Genetics, Laboratory for Translational Genetics, 3000, Leuven, Belgium

^h VIB, VIB Center for Cancer Biology, Laboratory for Translational Genetics, 3000, Leuven, Belgium

ⁱ Emergentec Biodevelopment GmbH, 1180, Vienna, Austria

^j Department of Clinical Pathology, Medical University of Vienna, 1090, Vienna, Austria

^k Department of Medical Oncology, Erasmus MC Cancer Institute, 3000 CA, Rotterdam, the Netherlands

ARTICLE INFO

Keywords:

Acquired platinum resistance

PRAME

Tumor specific antigen

TP53

p21 down-regulation

ABSTRACT

High grade serous ovarian cancer (HGSOC) is the most frequent type of ovarian cancer. Most patients have primary response to platinum-based chemotherapy but frequently relapse, which leads to patient death. A lack of well documented and characterized patient-derived HGSOC cell lines is so far a major barrier to define tumor specific therapeutic targets and to study the molecular mechanisms underlying disease progression. We established 34 patient-derived HGSOC cell lines and characterized them at cellular and molecular level. Particularly, we demonstrated that a cancer-testis antigen PRAME and Estrogen Receptor could serve as therapeutic targets. Notably, data from the cell lines did not demonstrate acquired resistance due to tumor recurrence that matched with clinical observations. Finally, we presented that all HGSOC had no or very low *CDKN1A* (p21) expression due to loss of wild-type *TP53*, suggesting that loss of cell cycle control is the determinant for tumorigenesis and progression. In conclusion, patient-derived cell lines reveal that PRAME is a potential tumor specific therapeutic target in HGSOC and counteracting the down-regulation of p21 caused by loss of wild-type *TP53* might be the key to impede disease progression.

1. Introduction

Epithelial ovarian cancer (EOC) is a rare disease with a worldwide incidence and mortality of 240000 and 150000, respectively [1]. 75%

of EOC are high grade serous ovarian cancers (HGSOC) that are often diagnosed at advanced stage. Standard of care includes debulking surgery and platinum-based therapy. Most patients show primary response; however the vast majority relapses with resistant disease, which

* Corresponding author. Ebene 5Q, AKH, Waehringuer Guertel 18-20, Translational Gynecology Group, Department of Obstetrics and Gynecology, Medical University of Vienna, 1090, Vienna, Austria.

E-mail address: dan.cacsire-castillo@meduniwien.ac.at (D. Cacsire Castillo-Tong).

¹ These authors contribute equally to the manuscript.

² Current affiliation: Medical University Innsbruck, Department of Internal Medicine IV, 6020 Innsbruck, Austria.

is defined as acquired resistance. Tumor cell proliferation cannot be controlled and patients die because of disease progression. The 5-year survival rate of patients with advanced HGSOc is below 40%. Resistance is considered the major cause of the patients' death [2]. In addition, platinum-based drugs kill large numbers of non-tumor cells, dramatically reducing patients' quality of life [3]. In order to improve ovarian cancer treatment, tumor specific targets have to be defined for the development of more efficient and less toxic therapies.

At the molecular level, common features of HGSOc include *TP53* mutations (96%) and loss of homologous recombination repair (HRR) due to mutational or epigenetic inactivation of the *BRCA1/2* or other HRR genes [4]. Aside from these common traits, HGSOcs are highly heterogeneous with large amounts of copy number changes and chromosomal rearrangements. The genetic instability and the loss of functional p53 and *BRCA1/2* have a direct consequence of higher number of mutations in tumor cells.

To better understand the mechanisms underlying the resistance of HGSOc, well characterized experimental models representing the cellular and genetic backgrounds of HGSOc are essential. Unfortunately, by comparing copy number changes, mutations and mRNA profiles with tumors, it was discovered that the cell lines historically used for ovarian cancer research were most unlikely to be representative of HGSOc [5,6]. For this reason, several groups including ourselves have previously attempted to establish HGSOc cell lines [6–11]. The number of the cell lines generated from these studies is rather low and with no systematic molecular analyses. The lack of linked clinical data about the donors is also a drawback to understand the impact of cellular and molecular characteristics on disease progression [12].

To address this challenge, we established 34 cell lines from 23 HGSOc patients and analyzed the acquired resistance in these tumors and the molecular mechanisms of disease progression. Furthermore, we investigated potential therapeutic targets using these models and validated the results using RNA sequencing data from 66 paired primary and recurrent HGSOc tumors published in a previous study [13]. The cell line models reveal that a cancer-testis antigen PRAME is a potential therapeutic target for HGSOc and the down regulation of p21 caused by the loss of wild-type *TP53* is the most important event for disease progression.

2. Materials and methods

2.1. Establishing and maintaining HGSOc cell lines and primary mesothelial cell culture

The methods of establishing and maintaining cell lines were published previously [11]. For tumor tissues, we abandoned the previous enzymatic digestion because of a very low success rate and used a cell scraper to release the tumor cells, which were collected by centrifugation. In some ascites, many mesothelial cells grew quickly covering the surface between tumor cell clusters in the culture flasks at the beginning passages. They detached very quickly upon trypsinization (< 2mins), while tumor cells needed longer to detach (> 5mins). Using selective trypsinization, we were able to isolate primary cell culture that predominantly contains mesothelial cells.

To authenticate the cell lines to patients, DNA finger printing was determined with PowerPlex 21 PCR Kit (Fitchburg, WI, USA), including 21 loci D1S1656, D2S1338, D3S1358, D5S818, D6S1043, D7S820, D8S1179, D12S391, D13S317, D16S539, D18S51, D19S433, D21S11, Amelogenin, CSF1PO, FGA, Penta D, Penta E, TH01, TPOX, and vWA [14] and compared to that of the germline DNA.

2.2. Extraction of DNA and RNA and cDNA synthesis

DNA and RNA were extracted with AllPrep DNA/RNA Mini Kit (QIAGEN, Venlo, The Netherlands). DNA from formalin-fixed, paraffin-embedded (FFPE) tissue and blood samples was isolated using QIAamp

DNA FFPE Tissue Kit (QIAGEN) and QIAamp DNA Mini Kit (QIAGEN). The quantity was determined by measuring the absorbance at 260/280 nm with Nanodrop 1000 (Thermo Fisher Scientific, Massachusetts, USA) and the quality of RNA was controlled using Agilent RNA 6000 Nano Kit (Agilent Technologies, CA, USA) and Agilent 2100 Bioanalyzer (Agilent Technologies). Samples with an RNA Integrity Number > 8 were further processed for RNA sequencing. cDNA was synthesized with Omniscript RT Kit (Qiagen).

2.3. Detection of mutations in the coding region of *TP53*, *KRAS* and *BRCA1/2*

Alterations in the coding regions of *TP53* and *KRAS* genes were examined by Sanger sequencing. For *TP53*, three DNA fragments C0 (sense: 5'-TGCTTCCAGCAGCGTGAC-3'; antisense: 5'-AGCAGCCTCTG GCATTCTG-3'), C1 (sense: 5'-CCTCCTCAGCATCTTATC-3', antisense: 5'-AAGAAGTGGAGAATGTCAG-3') and C2 (sense: 5'-CCAAGCAATGG ATGATT-3'; antisense: 5'-TAGTGGATGGTGGTACAGTC-3') covering exon 1-4, 4-7 and 6-11, were amplified with annealing temperatures of 55 °C, 50 °C and 52 °C, respectively. For *KRAS*, one single fragment covering the whole coding region (sense: 5'-ATTTCCGACTGGGAGC GAG-3'; antisense: 5'-GCATCATCAACACCCAGATTAC-3') was amplified with an annealing temperature of 60 °C with cDNA samples. PCR was performed with MangoMix (Bioline Reagent Ltd, London, UK) with 40 cycles of 30 s at 94 °C, 30 s at the corresponding annealing temperature, and 30 s at 72 °C. The reactions were preceded with a 10 min denaturation step and an extension at 72 °C for 10min. Mutations in the *BRCA1* and *BRCA2* coding regions were detected using TruSeq Custom Amplicon Design - AFP2, TruSeq Custom Amplicon Index Kit and Reagent Kit v2 (300cycles) and Illumina MiSeq System (Illumina; Inc., CA, USA). Once an alteration was found, it was verified with DNA or cDNA samples and confirmed in cell lines at different passages by Sanger sequencing.

2.4. Measurement of mutant DNA proportion by allele specific digital droplet PCR (ddPCR)

Allele specific ddPCR systems were designed to detect the absolute copy numbers of wild type and mutant *TP53* and *KRAS* in DNA samples. Primers and probes are shown in Supplementary Table S4. PCR was performed using ddPCR Supermix for Probes (Bio-Rad Laboratories, Inc., CA, USA) according to the manufacturer's instruction. Signals were detected by QX200 Droplet Digital PCR System (Bio-Rad Laboratories, Inc.). We used these systems to determine the tumor cell proportion in cell culture. Additionally, we performed these assays for cell lines at higher passages to ensure that all cells harbored their specific mutations.

2.5. Low coverage whole genome sequencing and RNA-sequencing and annotation

The methods were described in detail previously [11].

2.6. Determination of DNA copy number

DNA copy number of *TP53* and *BRCA1/2* were detected with the corresponding PrimPCR ddPCR Copy Number Assays (dHsaCP1000586, dHsaCP2500367, dHsaCP2500368, respectively, Bio-Rad, CA, USA) with *EIF2C1* (dHsaCP2500349) as reference gene following the manufacturer's instruction (Bio-Rad Laboratories, Inc.). DNA from a healthy individual was used as a control.

2.7. Unsupervised clustering

RNA sequencing data includes 63 samples from 33 cell lines with one line 17066 excluded because of bad quality of sequencing results.

Euclidean distance clustering was performed on the EDA normalized data using the top 10% of the expressed genes ranked by their standard deviation across the cohort.

2.8. Analyses of specific gene expression

Since cell lines with low passages had higher possibility to contain other types of cells, some of the samples were excluded according to the results of unsupervised clustering (indicated in Fig. 1). Mean expression was used for cell lines with more than one measurements at higher passages.

2.9. In vitro carboplatin sensitivity test

Chemo-sensitivity was measured by MTT assay using EZ4U-kit following the manufacturer's instructions (Biomedica, New Hampshire, USA). 7×10^3 cells per well were seeded in 96-well plates (Costar, Corning Incorporated, USA) and incubated with carboplatin (Accord Healthcare, North Harrow, UK) in triplicate at 37 °C and 5% CO₂ for 96 h. At least three independent experiments were performed for each cell line. IC₅₀ values were calculated using a non-linear dose-response curve with sigmoidal fit of logarithmic mean across the triplets of each assay by GraphPad Prism 5.00 for Windows (GraphPad Software, San Diego, CA, USA; www.graphpad.com). Carboplatin concentrations ranging from 100 µg/ml (270 M) to 0.4 µg/ml (1.08 µM) with 1:2 serial dilution between them were used in the initial test. We chose this range of concentrations, as the plasma peak value of carboplatin used for patients is around 300 µM. If the cells showed borderline values of sensitivity, higher or lower concentrations were included in additional tests.

2.10. Comparison of gene expression in two different groups of cell lines

We compared the gene expression in tumor cells established before and after exposing to carboplatin-based therapy and tumors with or without wild-type *BRCA1/2*. For the latter, means were calculated in case more than one cell line was established from the same patient. The `nbinomTest` function of the DESeq R package was used after normalization for the identification of differentially expressed transcripts [15]. p-values were adjusted using Benjamini Hochberg methods thus controlling the false discovery rate (FDR). Transcripts with an FDR < 5%, a fold-change value > |5|, and read counts > 50 in the group showing higher read counts were considered as relevant.

2.11. Selection of potential tumor specific antigens

We selected genes coding for potential tumor specific antigens mainly from four sub-groups: (i) Cancer-testis like antigens (CTA); (ii) Differentiation antigens; (iii) Oncofetal antigens including α -fetoprotein, carcinoembryonic antigen (CEA), trophoblast glycoprotein, onco-trophoblast, and solid tumor associated glycoprotein; (iv) Over-expressed antigens, mainly based on the information provided by Even-Desrumeaux et al. [16,17]. Particularly, for CTAs, we referred the 118 genes described as “testis-selective” or “testis restricted” in the CTDatabase maintained by The Ludwig Institute for Cancer Research (<http://www.cta.lncc.br/>).

2.12. Measurement of PRAME gene expression by RT-qPCR

TaqMan Assay Gene Expression Hs01022301_m1 was used to measure the *PRAME* expression in cell lines according to manufacturer's instructions. A cell line with relative high expression of *PRAME* (according to RNA sequencing data) was used to make a dilution series to generate a standard curve. Relative expression values were calculated in fold of the standard samples. Cell line data were median-normalized for comparison of RT-qPCR results with RNA sequencing results.

2.13. Immunohistochemistry staining and immunofluorescent staining

Immunohistochemistry was performed as described previously [11]. Antibodies against PRAME (PA5-13679; Thermo Fischer Scientific) and EpCAM (ab32329; abcam, Cambridge, UK) was diluted at 1:400 and 1:500 in Dako Antibody-Diluent (Agilent Technologies), respectively, and incubated with the slides at 4 °C overnight. Immunofluorescent staining (IF) was performed on slides pretreated with adhesion substance (Paul Marienfeld GmbH & Co. KG, Lauda-Königshofen, Germany). 50000 cells were subjected to each well on the slides following the instruction of the manufacturer, dried and fixed in 4% paraformaldehyde. The slides were treated with 0.5% Triton X-100 in PBS, washed 3 times with PBS, each time for 3 min and incubated with Dako Ultra Vision Block (Thermo Fischer Scientific) for 7 min at RT followed by washing in PBS-Tween 20 twice, each for 3 min. The PRAME antibody was diluted at 1:100 in Dako Antibody-Diluent and incubated at 4 °C overnight. Alexa Fluor 488 goat anti-Rabbit IgG (Thermo Fisher Scientific) was diluted 1:500 in Dako Antibody-Diluent and incubated for an hour at RT. DAPI staining was performed with standard protocol and the slides were mounted with Fluoromount-G (Southern Biotech, Birmingham, USA).

2.14. Data and materials availability

We are willing to distribute any materials (cell lines), data (RNA sequencing, low coverage sequencing, patient clinicopathological data) and protocols in the published experiments to qualified researchers for their own use upon reasonable request.

3. Results

3.1. HGSOC cell lines and patients

34 tumor cell lines from ascites, tumor tissue and pleural fluid from 23 patients with HGSOC were established (Table 1). Part of the results regarding seven of them was reported previously [11].

From five patients (P3, P9, P12, P16, P17), we established more than one cell line from tumor material collected either from different locations or at different time points (Table 1). We also cultivated primary mesothelial cells from the ascites of eight patients, which could be passaged approximately 10 times until they underwent senescence or died. Their cell type identity was confirmed by pathologists (Supplementary Fig. S1). In addition, they expressed very high level of *CALB2* (> 4000 read counts), which is a marker for mesothelial cells, and had little or no expression of *EPCAM* (26-692 read counts). This was in contrast to tumor cells, which had very high *EPCAM* expression (1781-47851 read counts) and no or very low *CALB2* expression (0-304 read counts). Furthermore, they had wild-type *TP53*, while their counterpart tumor cells harbored mutant *TP53* (see also 3.2).

All cell lines were authenticated to be from the corresponding patients by DNA finger printing analyses (Supplementary Table S1). The purity of the tumor cells was determined by allele specific digital droplet PCR systems measuring the proportions of tumor specific mutant *TP53* or *KRAS* DNA copies. All cell lines have been passaged over 30 times.

3.2. The cell lines are stable experimental models for HGSOC

In all cell lines except one, unique *TP53* alterations affecting the transcripts were detected and no wild type allele could be found (Table 1, Supplementary Table S2). The alterations in mRNA were derived either directly from DNA or from intronic changes leading to variant splicing. p53 protein was truncated with variant C-terminals or affected by substitution or deletion of amino acids. All *TP53* alterations were located in the DNA binding domain except in patients P4 and P6, whose tumors had alterations in the oligomerization domain

Table 1
Information on clinical data of the patients and gene mutations of the tumors.

Cell line	Patient number	Patient age at primary diagnosis	Time of sample collection ^{*1}	Exposed to platinum-based drugs ^{*2}	Original material ^{*3}	Residual tumor ^{*4}	Response at completion of 1st line chemotherapy ^{*5}	Response 6 months after 1st line treatment ^{*5}	Recurrence ^{*6}	Progression free interval (days)	Death ^{*6}	Overall survival (days)	TP53 ^{*7}	BRCA1 ^{*7}	BRCA2 ^{*7}	KRAS ^{*7}
8587	1	49	P	0	T	0	cCR	cCR	0	1993	0	2119	1	0	0	0
12370	2	67	P	0	A	1	cPR	NA	P	0	1	275	1	0	0	0
13363	3	33	P	0	A	1	cPR	cPD	P	0	1	473	1	0	0	0
15233_nov			R	1	A								1	0	0	0
13699	4	53	P	0	A	0	cCR	cCR	1	301	0	2059	1	0	0	0
13781	5	58	P	0	A	1	cCR	cPD	1	107	1	887	1	0	1	0
13914	6	66	P	0	A	0	cCR	NA	1	309	1	880	1	1	0	0
14433	7	61	P	0	A	0	cCR	cPD	1	216	0	1727	1	0	1	0
8540	8	44	PR	1	A	1	cPR	cPR	P	0	1	1194	0	0	0	2
15876	9	79	PR	1	A	NA	cPR	NA	P	0	1	390	1	0	0	0
16106			PR	1	A								1	0	0	0
17066			PR	1	A								1	0	0	0
17201			PR	1	A								1	0	0	0
17268			PR	1	A								1	0	0	0
EB			PR	1	A								1	0	0	0
8684	10	68	P	0	T	0	cCR	cCR	1	600	1	1209	1	0	0	0
16471	11	58	P	0	A	1	cCR	cCR	1	255	1	529	1	0	1	0
17142	12	50	PR	1	P	0	cCR	cCR	1	310	1	1876	1	0	0	0
17249			PR	1	A								1	0	0	0
17330	13	68	P	0	A	1	cCR	cPD	1	167	1	1296	1	0	0	0
17399	14	72	P	0	A	0	cCR	cPD	1	108	1	488	1	0	0	0
8713	15	75	P	0	T	1	NA	NA	NA	NA	0	56	1	0	2	0
8714	16	55	P	0	T	1	cPR	cPD	P	0	1	466	1	0	0	0
17457			P	0	A								1	0	0	0
EK_R1			PR	1	P								1	0	0	0
17480	17	63	P	0	A	1	cCR	cCR	0	1166	0	1326	1	0	1	0
8715			P	0	T								1	0	1	0
8716			P	0	T								1	0	1	0
8724	18	68	P	0	T	1	cCR	cCR	1	223	1	674	1	0	2	0
8732	19	52	P	0	T	1	NA	NA	NA	NA	1	416	1	0	0	0
17978	20	85	PR	1	A	NA	cCR	cPD	1	209	1	541	1	0	0	0
18483	21	54	R	1	A	1	cCR	cCR	1	273	1	1471	1	0	0	0
18507	22	76	P	0	A	0	cCR	cCR	1	209	1	679	1	0	0	0
18605	23	65	P	0	A	1	NA	NA	P	0	1	175	1	0	0	0

*1: Time of sample collection; P: at primary diagnosis; R: at recurrence; PR: at subsequent disease progression.

*2: Exposed to platinum-based drugs: 0: no; 1: yes.

*3: Original material: T: tumor tissue; A: ascites; P: pleural fluid.

*4: Residual tumor: 0: no residual tumor; 1: macroscopically visible tumor; P9 and P20 did not have surgery.

*5: Response: cCR: clinical complete response; cPR: clinical partial response; cPD: clinical progressive disease; NA: not applicable or not available.

*6: Recurrence, Death: 0: no; 1: yes; p: progressive disease; NA: not adjustable or not available; all cases of death were cancer related.

*7: mutations in tumor cells: 0: wild type; 1: homozygous; 2: heterozygous.

(Supplementary Fig. S2). Germline *BRCA1* and *BRCA2* mutations were detected in one (P6) and three (P5, P7, P11) of these cell lines, respectively, all losing wild-type alleles in tumor cells. Patient P17 presented with a somatic *BRCA2* mutation with loss of heterozygosity. In addition, P15 had a heterozygous germline *BRCA2* mutation, which was retained in the corresponding tumor. The tumor cells from P18 harbored a heterozygous somatic *BRCA2* mutation. The only *TP53* wild-type cell line 8540 had a heterozygous *KRAS* mutation. We re-examined two FFPE blocks and confirmed the high grade serous histological type (Supplementary Fig. S3). The genetic profile of the FFPE samples, the cell lines and the patient blood sample were confirmed by DNA fingerprinting analyses. Both mutant and wild-type DNA copies of *KRAS* were detected in DNA samples isolated from FFPE sections by allele specific ddPCR. Sanger Sequencing confirmed that the status of *TP53*, *BRCA1/2* and *KRAS* mutations was unchanged in different cell lines established from the same patients and remained stable through passaging.

Low coverage sequencing revealed that all *TP53* mutant cell lines had a high incidence of copy number alterations (CNA) compared to their corresponding germline DNA, e.g. P_16099B. The *TP53* wild-type and *KRAS* mutant cell line P8_8540 had less CNA than the *TP53* mutant cell lines. Nevertheless, cell lines established from the same patients presented similar pattern of CNA (Supplementary Fig. S4).

Unsupervised clustering of gene expression profiles of 63 RNA samples including cell lines with different passages (Fig. 1) revealed that (i) the primary mesothelial cell cultures had different expression profiles than all tumor cell lines; (ii) different passages of the same tumor cell lines had very similar expression profiles; (iii) cell lines derived from the same patient had the most similar expression profiles, regardless of whether they were derived from different locations (e.g. Patient P17) or whether they were established at different time points of disease progression (e.g. Patients P3, P9, and P12).

3.3. Cell cycle pathway is the determinant for tumorigenesis and tumor progression

We first examined genes, whose transcription is directly regulated by p53 and found that major genes controlling cell cycle arrest, apoptosis, survival and senescence *CDKN1A* (*p21*), *BAX*, *TIGAR*, *PAI1* and *MDM2* were all down-regulated in the *TP53* mutant tumor cells in comparison with the *TP53* wild type cell line 8540 and the mesothelial cells (Fig. 2A–E). Furthermore, cyclins controlling the cell cycle restraint points *cyclin D1* (*CCND1*), *E1* (*CCNE1*), *A1* (*CCNA1*) and *B2* (*CCNB2*) were overexpressed in all tumor cells. No obvious differences could be observed regarding the expression of other cyclins (Fig. 2F–O). The *KRAS* mutant cell line 8540 showed additional higher expression of *cyclin D2* (*CCND2*) (Fig. 2G) in comparison to all other cell lines.

3.4. Response to carboplatin in vitro and in vivo

Most of the tumor cell lines showed lower IC_{50} values for carboplatin than the primary mesothelial cell cultures, indicating that carboplatin preferentially kills tumor cells (Fig. 3A). A few cell lines showed very high values (8684, 18483). Different cell lines from the same patients presented different pattern of changes of the IC_{50} values. Some became more resistant in later established lines (e.g. 15233_nov was collected 12 months later than 13363; 17249 was collected 20 days later than 17142), while others showed the opposite change and became more sensitive (e.g. the 6 cell lines from P9 were derived from ascites isolated over a total interval of 12 months; EK_R1 was taken 6 months later than 8714 and 17457). Cell lines from P17 were established from ascites (17480) and tumor tissues (8715, 8716) at primary diagnosis and showed similar sensitivities.

Seven patients had no residual tumors after primary surgery,




Fig. 1. Unsupervised clustering of 63 samples. M in the color column indicates five primary cell cultures mostly including mesothelial cells. The number in the colored frames indicates the patient number. Passages of the cell lines were indicated after “#”. Asterisks indicate the samples, which are excluded for further analyses. The close brackets indicate the samples, from which the means are calculated for further analyses. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)




Fig. 2. Expression of determinant genes in different groups of cells. Y-axis indicates the gene expression values obtained from RNA sequencing (read counts). M, T and 8540 represent primary mesothelial cell cultures, tumor cell lines with mutant *TP53* and cell line 8540 with wild-type *TP53* and a *KRAS* mutation, respectively. Box includes all values between quartile 1 to quartile 3. By “T”, the 90th and the 10th percentile are shown and the outliers are indicated by dots. By “M”, the individual values are shown in dots and the mean value is indicated by a bar.

presented a clinical complete remission at the completion of the first line treatment, and then developed recurrent disease. From six of these patients, we established cell lines from primary tumor material. By comparing the IC_{50} value with the progression free interval (PFI), no correlation could be observed between the two parameters (Fig. 3B).

We further examined clinical data of all patients (Supplementary Fig. S5). 10 patients had at least one recurrence (red colored) and received at least 2 lines of platinum-based treatment. The CA-125 dropped upon the treatment of platinum-based drug by almost all cycles with a few exceptions during the whole treatment.

In addition, we did not observe particularly low IC_{50} values of the cell lines with *BRCA1* or *BRCA2* mutations (Fig. 3A). By comparing

gene expression profiles of the cell lines from the 5 patients with only mutant *BRCA1/2* and the remaining 18 patients with at least one wild type *BRCA1/2* allele, we did not find any differentially expressed genes between the two groups, even after lowering the fold change (FC) threshold to 2.

Moreover, we compared gene expression profiles of cell lines with and without exposure to chemotherapy treatment and we found that only one gene *NBL1* was overexpressed in the exposed cells and eight transcripts were overexpressed in the naive cells, all being non-coding RNA genes (*RP5-1114G22.2*, *FAM103A2P*, *OVAAL*, *RP11-527N22.1*, *DDX11L9*, *RP11-438N16.1*, *H19*, *AC004540.4*). By lowering the fold change (FC) threshold from 5 to 2, the results were unchanged.




Fig. 3. Sensitivity of the cell lines to carboplatin. A. IC₅₀ values obtained by *in vitro* chemosensitivity tests. The left cluster of cell lines are those established only once from one patient; each of the five clusters in the middle includes cell lines established from the same patient. The cluster at the right contains five primary mesothelial cell cultures. The circle indicates the cell line with *BRCA1* mutation, while the dots indicate the lines with *BRCA2* mutations. The asterisks indicate the lines, which were derived from tumor material already exposed to carboplatin treatment. The values are shown as mean \pm SD. P indicates the patient number. B. Comparison of the IC₅₀ values with PFI of the corresponding patients. All patients in this selected group had no macroscopically visible residual tumor after surgery, had clinical complete remission after completing the first line treatment and had developed recurrent disease. The corresponding cell lines were derived from tumor material collected at primary diagnosis. The cell lines are arranged in the way with decreased IC₅₀ values from top to bottom.

3.5. PRAME and the estrogen receptor (ER) are potential therapeutic targets for HGSOc

We selected a panel of tumor associated antigens including cancer-testis like antigens, differentiation antigens, oncofetal antigens and some known cancer related overexpressed antigens [16,17] and examined their expression in tumor cell lines in comparison with the five mesothelial cell cultures. Most of the genes had no or little expression in all samples (Supplementary Table S3; *AFP*; *BAGE2*; *CEACAM3*, 4, 5, 7, 8, 16, 18, 20, 21; *CEACAMP1*, 2, 5, 7, 8, 9, 11; *MAGEA3*, *A12*, *B2*, *C1*; *MUC2*, *3A*, *5AC*, *12*, *13*, *19*; *PSG1*; *TEX15*; *TLX1*, 2, 3). Some had comparable high expression in both tumor cells as well as in the mesothelial cells (e.g. *EGFR*, *ERBB2*, *MGAT5*, *MUC16*, *SPAG9*, *TPBG*, *TSPYL1*). 27 genes were found to be higher expressed in tumor cells than in mesothelial cells, but with different prevalence. Three had low expression in tumors and high expression in mesothelial cells and 16 had rather low prevalence of highly expressing tumors (Table 2). Four genes *MAGEA4*, *MAGEA11*, *MUC4* and *SPAG1* had high expression in less than 50% of the samples. Four genes had high prevalence in all tumors, among which *FOLR1*, *MUC1* and *MUC20* are expressed in multiple organs/tissues, such as kidney, salivary gland, lung, or fallopian tube (<https://www.proteinatlas.org>; <https://www.genecards.org>). *PRAME* was highly expressed in 94% of all tumor cell lines but not in the mesothelial cells. It was reported to be only expressed in testis tissue and to a lesser extent in ovary [18,19]. *PRAME* was not expressed in 8540 and had a very low expression in 18605 (Fig. 4A). Evaluation of

the RNA sequencing data with RT-qPCR confirmed that *PRAME* indeed had very high expression in 31/33 cell lines and was not expressed in mesothelial cells and fibroblasts (Fig. 4B). By examining the RNA sequencing data from 66 matched primary and recurrent HGSOc tumor tissues from a previous study [13], high expression of *PRAME* was confirmed (Fig. 4C) in almost all tumors. A few samples showed lower expression in both samples or in one of the matched samples (Fig. 4D).

Immunohistochemistry and immunofluorescent staining of the corresponding tumor tissues showed that *PRAME* protein was expressed in nucleus, cytoplasm and at the membrane of the tumor cells (Fig. 5).

Additionally, the gene coding for ER, *ESR1* showed higher expression in *TP53* mutant tumor cells and was low in 8540 and the mesothelial cells (Fig. 2P). There was no or very low expression of the progesterone receptor (*PGR*) in *TP53* mutant tumor cells (read counts: median = 1, q1 = 0, q3 = 23) and 8540 (read count: 3).

4. Discussion

We successfully established 34 patient-derived HGSOc cell lines and characterized them at the cellular and molecular level. With these new cell lines, we provide useful models to the scientific community to study the tumorigenesis and progression of HGSOc. Particularly, we demonstrated that a cancer-testis antigen *PRAME* and the ER could serve as therapeutic targets. The experimental results did not show acquired resistance of recurrent tumors, which was in line with the clinical observations. Finally, we presented that all HGSOc had no or very low

Table 2
Analysis of potential therapeutic targets.

ENSEMBL gene ID	official gene symbol	relative low expression in tumors (q3 < 1000) AND relative high expression in mesothelial cells (max. > 100)	low prevalence of highly expressing tumors (< 30%)	middle prevalence (30%–50%)	high prevalence (> 70%) AND in multiple organ tissues expressed	high prevalence (94%) AND only expressed in testis
ENSG00000079385	CEACAM1	X				
ENSG00000186567	CEACAM19	X				
ENSG00000197279	ZNF165	X				
ENSG00000104327	CALB1		X			
ENSG00000086548	CEACAM6		X			
ENSG00000198681	MAGEA1		X			
ENSG00000197172	MAGEA6		X			
ENSG00000124260	MAGEA10		X			
ENSG00000046774	MAGEC2		X			
ENSG00000117983	MUC5B		X			
ENSG00000184956	MUC6		X			
ENSG00000169550	MUC15		X			
ENSG00000185664	PMEL		X			
ENSG00000183206	POTEC		X			
ENSG00000196604	POTEF		X			
ENSG00000196834	POTEI		X			
ENSG00000181433	SAGE1		X			
ENSG00000155761	SPAG17		X			
ENSG00000241697	TMEFF1		X			
ENSG00000147381	MAGEA4			X		
ENSG00000185247	MAGEA11			X		
ENSG00000145113	MUC4			X		
ENSG00000104450	SPAG1			X		
ENSG00000110195	FOLR1				X	
ENSG00000185499	MUC1				X	
ENSG00000176945	MUC20				X	
ENSG00000185686	PRAME					X

CDKN1A (p21) expression due to loss of wild type *TP53*.

Since Domcke et al. [5] pointed out that many of the ovarian cancer cell lines historically used for research are unlikely to be of high grade serous origin, great efforts have been paid to establish patient-derived new models including cell lines and patient-derived xenografts. The current study presents 34 new cell line models, analyzed at the level of transcriptomics, CNV profile and mutations of *TP53*, *BRCA1/2* and *KRAS* genes that are linked to clinicopathological information, treatment, and response of the patients.

Despite extensive research and the introduction of some additional therapeutic options such as Bevacizumab, ovarian cancer remains a cancer with poor prognosis [20]. Carboplatin is still the gold standard treatment for HGSOC, which kills cells nonspecifically and is highly toxic [3]. So far, identifying tumor specific targets has been a big challenge for the scientific community. Some proteins, such as the Wilms tumor protein, could not serve as an optimal target, since they are not only highly expressed in ovarian cancer cells, but also in the mesothelium [21]. An ideal therapeutic target should have a homogeneous expression in tumors and no or minimal expression in normal tissues [16]. Thus, we examined the expression levels of a panel of genes coding for possible tumor associated antigens and some membrane proteins. Four genes, *MUC1*, *MUC20*, *FOLR1* and *PRAME* with high expression levels and high prevalence across all tumor cell lines were identified. Among these four genes, *MUC1* is expressed in almost all epithelial tissues and in some hematopoietic cells [22] and *MUC20* was detected in multiple organs, such as kidney, lung, liver, and the digestion system [23]. Expression of *FOLR1* was also found in normal tissues such as kidney, bladder, salivary glands, lung and some cells of the nerve system [24]. In contrast to the multiple tissue expression of these three genes, *PRAME* expression is only found in normal testis tissues and to a lesser extent in the ovary. Since the ovaries of the HGSOC patients were affected by tumors and are usually removed during surgery, targeting *PRAME* would not affect normal tissues. Our results also showed that *PRAME* was not expressed in mesothelial cells lining the peritoneal cavity and in fibroblasts, which makes *PRAME* an


optimal target for therapy development.

PRAME, the preferentially expressed antigen in melanoma gene, was first detected in a mRNA study of human testis [25]. It codes a membrane-bound protein and triggers autologous cytotoxic T cell-mediated immune responses, presumably through retinoic acid signaling [18,26,27]. Its overexpression in several solid tumors, such as melanoma [28], breast cancer [19], and sarcomas [29,30] as well as in hematological malignancies [27] makes it an interesting therapeutic target. Recent studies using recombinant *PRAME* and an immunostimulant demonstrated a cellular immune response in patients in addition to safety [31,32]. Furthermore, a polyclonal antibody was produced against *PRAME* and was shown to bind recombinant *PRAME ex vivo* as well as different cells *in vitro* [33]. In ovarian cancer, *PRAME* was found to be frequently expressed in epithelial cancer at both mRNA and protein levels, which was regulated by DNA methylation [34], and to have prognostic value for stage III serous cancer [35–37]. Further investigation will be needed to understand the expression activation and functions of *PRAME* in *TP53* mutant HGSOC to provide the basis for drug development, for which the new patient-derived cell lines presented in this study are ideal models.

Patients with serous ovarian cancer that have positive hormonal receptor status were shown to have worse survival than those with negative receptor status [38]. Since the ovary produces estrogen, which could promote cell growth upon binding to its receptor ER, we also examined the expression level of *ESR1* gene and found a high expression of this gene in most of the *TP53* mutant tumor cell lines. Endocrine therapy was shown to bring benefits to patients with advanced epithelial ovarian cancer [39], probably by blocking the *ESR1* promoted tumor cell growth. Even though the effect was not specified to HGSOC, it is worth further investigation in a well-defined population. Using our cell line models, the transcriptional regulation of *ESR1* could be further studied.

Originally, platinum resistance was defined for tumors, which recur within 6 months after completing first line therapy [40]. This concept of clinical resistance, however, does not necessarily associate with the

PRAME mRNA expression



(caption on next page)

Fig. 4. *PRAME* gene expression. HGSOC: high grade serous ovarian cancer cell lines, ordered as explained in Fig. 3; M: mesothelial cell cultures; F: cell cultures containing mainly fibroblasts; OVCAR3 (NIH:OVCAR-3): an ovarian cancer cell line purchased from ATCC (ATCC HTB-161). 4A. *PRAME* expression in cell lines measured by RNA sequencing. 4B. Relative *PRAME* expression measured by RT-qPCR. 4C. *PRAME* expression of 66 pairs of matched primary and recurrent HGSOC tumor tissues measured by RNA sequencing. The bars present q1, median and q3; 4D. Correlation of *PRAME* expression in matched primary and recurrent samples. *PRAME* expression obtained from RNA sequencing in the 66 primary tumors are plotted against the corresponding recurrent ones. The triangles indicate two pairs of tumors both with low *PRAME* expression; the rhombus indicates a pair with low *PRAME* in recurrent tumor and higher value in primary sample; the squares indicate two pairs with low values in primary samples and high values in recurrent tumors.

response of tumor cells to drug. Other possible reasons for a rapid recurrence of tumors could be the quick exponential proliferation or/and higher number of living tumor cells after therapy due to poor accessibility of the drug. This clinical definition of resistance was equated to a cellular resistance in 2011 for ovarian cancer [41], while the hypotheses of acquired resistance and the evolution of resistance were proposed. Our cell line models showed that recurrent tumor cells did not become more “resistant” to carboplatin than their primary counterparts, which was in accordance with patient response presented by clinical data, suggesting that recurrent tumors resemble their primary ancestors. Molecular analyses of their transcriptional profiling and CNV profiles further suggest the similarities of the primary and recurrent tumor cells. Nevertheless, the current study included a small cohort of 23 patients and establishing cell lines might involve selections of tumors with distinct molecular characteristics. Thus, evaluation in a larger cohort of patients will be needed to clarify this issue.

By examining genes, whose transcription is directly regulated by p53 [42], a clear down regulation was observed for the key genes, which regulate the cell cycle (p21, *CNKN1A*), apoptosis (*BAX*), senescence (*PAI1*) [43] and survival (*TIGAR*) [44] in all *TP53* mutant cell

lines, indicating that the loss of wild-type p53 functions is the major driving force of tumor cell progression. We also observed higher expression of genes coding for cyclins D1 (*CCND1*), E1 (*CCNE1*), A1 (*CCNA1*) and B2 (*CCNB2*), demonstrating that *TP53* mutant tumor cells had a high endogenous level of all cyclins needed to pass the G1/S and G2/M restriction points. Synchronized with the down-regulation of p21, the inhibitor of the cyclin and the cyclin-dependent kinase complexes, tumor cells lost the restraints in their cell cycle and were directed to proliferation. Our data suggest that loss of the wild-type *TP53* is not only the reason for tumorigenesis but also the driver of tumor progression. Although well established, we confirmed in the current study that all these cellular processes are common for all *TP53* mutant HGSOC. It is important to emphasize on the determinant role of cell cycle control in HGSOC, so that efforts could be directed towards the main reason of disease progression in the development of new therapies.

Taken together, we (i) established and molecularly analyzed 34 cell lines from 23 HGSOC patients, (ii) showed that loss of *TP53* wild type was the main driving force of tumorigenesis and tumor progression, and (iii) identified *PRAME* as a potential therapeutic target. The cell line




Fig. 5. *PRAME* protein expression in FFPE samples and in cell lines. The coding of the patients is indicated on top of each picture. The scale is indicated in the first picture on top-left with a single exception of HE staining of tumors from P8, which showed a clear HGSOC histologic type. The cell line derived from this tumor has wild-type *TP53* and a *KRAS* mutation, which is considered to be typical for low-grade serous cancer.

models can be applied for therapy development in addition to the investigation of molecular mechanisms in disease progression.

Author contributions

Conceptualization, C.K., I.V.D.D., E.I.B., P.C., C.G., D.L., E.M.B. and D.C.C-T; Methodology, C.K., I.V.D.D., A.W., M.G., J.A.K., J.U.K., S.P., A.R., C.G., C.F.S., D.S., R.H., B.B., and P.P.; Formal Analysis, B.B. and P.P.; Investigation, C.K., I.V.D.D., A.W., M.G., J.A.K., J.U.K., S.P. and D.C.C-T; Resources, A.R., C.G., T.B. and R. H.; Data curation, C.K., I.V.D.D., A.W., M.G., J.A.K., J.U.K., S.P., D.L., D.S., and B.B.; Writing - original Draft C.K., I.V.D.D. and D.C.C-T; Writing - Review & Editing, C.K., I.V.D.D., C.G., E.I.B., P.C., C.G., D.S., E.M.B. and D.C.C-T; Visualization, I.V.D.D. and B.B.; Project Administration and Supervision, D.C.C-T; Funding Acquisition, E.I.B., C.G., D.L., E.M.B. and D.C.C-T.

Declaration of interest

All authors declare that we have no financial conflict of interest that might be construed to influence the results or interpretation of the manuscript.

Acknowledgements

This work was supported by European Commission's Seventh Framework Programme under grant agreement No. 279113 (OCTIPS; www.octips.eu). All authors declare that we have no financial conflict of interest that might be construed to influence the results or interpretation of the manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.canlet.2019.05.032>.

References

- [1] D.D. Bowtell, S. Bohm, A.A. Ahmed, P.J. Aspuria, R.C. Bast Jr., V. Beral, J.S. Berek, M.J. Birrer, S. Blagden, M.A. Bookman, J.D. Brenton, K.B. Chiappinelli, F.C. Martins, G. Coukos, R. Drapkin, R. Edmondson, C. Fotopoulou, H. Gabra, J. Galon, C. Gourley, V. Heong, D.G. Huntsman, M. Iwanicki, B.Y. Karlan, A. Kaye, E. Lengyel, D.A. Levine, K.H. Lu, I.A. McNeish, U. Menon, S.A. Narod, B.H. Nelson, K.P. Nephew, P. Pharoah, D.J. Powell Jr., P. Ramos, L.L. Romero, C.L. Scott, A.K. Sood, E.A. Stronach, F.R. Balkwill, Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer, *Nat. Rev. Canc.* 15 (2015) 668–679.
- [2] E.M. Berns, D.D. Bowtell, The changing view of high-grade serous ovarian cancer, *Cancer Res.* 72 (2012) 2701–2704.
- [3] M.G. Apps, E.H. Choi, N.J. Wheat, The state-of-play and future of platinum drugs, *Endocr. Relat. Cancer* 22 (2015) R219–R233.
- [4] N. Cancer Genome Atlas Research, Integrated genomic analyses of ovarian carcinoma, *Nature* 474 (2011) 609–615.
- [5] S. Domcke, R. Sinha, D.A. Levine, C. Sander, N. Schultz, Evaluating cell lines as tumour models by comparison of genomic profiles, *Nat. Commun.* 4 (2013) 2126.
- [6] M.S. Anglesio, K.C. Wiegand, N. Melnyk, C. Chow, C. Salamanca, L.M. Prentice, J. Senz, W. Yang, M.A. Spillman, D.R. Cochrane, K. Shumansky, S.P. Shah, S.E. Kaloger, D.G. Huntsman, Type-specific cell line models for type-specific ovarian cancer research, *PLoS One* 8 (2013) e72162.
- [7] L.J. Letourneau, M.C. Quinn, L.L. Wang, L. Portelance, K.Y. Caceres, L. Cyr, N. Delvoe, L. Meunier, M. de Ladurantaye, Z. Shen, S.L. Arcand, P.N. Tonin, D.M. Provencher, A.M. Mes-Masson, Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer, *BMC Canc.* 12 (2012) 379.
- [8] Z. Pan, J. Hooley, D.H. Smith, P. Young, P.E. Roberts, J.P. Mather, Establishment of human ovarian serous carcinomas cell lines in serum free media, *Methods* 56 (2012) 432–439.
- [9] T. Sueblinvong, R. Ghebre, Y. Iizuka, S.E. Pambuccian, R. Isaksson Vogel, A.P. Skubitz, M. Bazzaro, Establishment, characterization and downstream application of primary ovarian cancer cells derived from solid tumors, *PLoS One* 7 (2012) e50519.
- [10] T.A. Ince, A.D. Sousa, M.A. Jones, J.C. Harrell, E.S. Agoston, M. Krohn, L.M. Selfors, W. Liu, K. Chen, M. Yong, P. Buchwald, B. Wang, K.S. Hale, E. Cohick, P. Sergent, A. Witt, Z. Kozhekbaeva, S. Gao, A.T. Agoston, M.A. Merritt, R. Foster, B.R. Rueda, C.P. Crum, J.S. Brugge, G.B. Mills, Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours, *Nat. Commun.* 6 (2015) 7419.
- [11] C. Kreuzinger, M. Gamperl, A. Wolf, G. Heinze, A. Geroldinger, D. Lambrechts, B. Boeckx, D. Smeets, R. Horvat, S. Aust, G. Hamilton, R. Zeillinger, D. Cacsire Castillo-Tong, Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer, *Cancer Lett.* 362 (2015) 218–228.
- [12] F. Jacob, S. Nixdorf, N.F. Hacker, V.A. Heinzelmann-Schwarz, Reliable in vitro studies require appropriate ovarian cancer cell lines, *J. Ovarian Res.* 7 (2014) 60.
- [13] C. Kreuzinger, A. Geroldinger, D. Smeets, E.I. Braicu, J. Sehouli, J. Koller, A. Wolf, S. Darb-Esfahani, K. Joehrens, I. Vergote, A. Vanderstichele, B. Boeckx, D. Lambrechts, H. Gabra, G.B.A. Wisman, F. Trillsch, G. Heinze, R. Horvat, S. Polterauer, E. Berns, C. Theillet, D. Cacsire Castillo-Tong, A complex network of tumor microenvironment in human high-grade serous ovarian cancer, *Clin. Cancer Res.* 23 (2017) 7621–7632.
- [14] M.G. Eisenberger, C.R. Hill, R.S. McLaren, C.J. Sprecher, D.R. Storts, Developmental validation of the PowerPlex(R) 21 system, *For. Sci. Int. Genet.* 9 (2014) 169–178.
- [15] S. Anders, W. Huber, Differential expression analysis for sequence count data, *Genome Biol.* 11 (2010) R106.
- [16] K. Even-Desrumeaux, D. Baty, P. Chames, State of the art in tumor antigen and biomarker discovery, *Cancers* 3 (2011) 2554–2596.
- [17] N. Beauchemin, A. Arabzadeh, Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis, *Cancer Metastasis Rev.* 32 (2013) 643–671.
- [18] H. Ikeda, B. Lethé, F. Lehmann, N. van Baren, J.F. Baurain, C. de Smet, H. Chambost, M. Vitale, A. Moretta, T. Boon, P.G. Coulie, Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor, *Immunity* 6 (1997) 199–208.
- [19] M.T. Epping, A.A. Hart, A.M. Glas, O. Krijgsman, R. Bernards, PRAME expression and clinical outcome of breast cancer, *Br. J. Canc.* 99 (2008) 398–403.
- [20] S. Mahner, L. Woelber, V. Mueller, I. Witzel, K. Prieske, D. Grimm, V.A.G. Keller, F. Trillsch, Beyond Bevacizumab: an outlook to new anti-angiogenics for the treatment of ovarian cancer, *Front. Oncol.* 5 (2015) 211.
- [21] C. Barcena, E. Oliva, WT1 expression in the female genital tract, *Adv. Anat. Pathol.* 18 (2011) 454–465.
- [22] A.M. Sousa, P.M. Grandgenett, L. David, R. Almeida, M.A. Hollingsworth, F. Santos-Silva, Reflections on MUC1 glycoprotein: the hidden potential of isoforms in carcinogenesis, *APMIS* 124 (2016) 913–924.
- [23] T. Higuchi, T. Orita, S. Nakanishi, K. Katsuya, H. Watanabe, Y. Yamasaki, I. Waga, T. Nanayama, Y. Yamamoto, W. Munger, H.W. Sun, R.J. Falk, J.C. Jennette, D.A. Alcorta, H. Li, T. Yamamoto, Y. Saito, M. Nakamura, Molecular cloning, genomic structure, and expression analysis of MUC20, a novel mucin protein, up-regulated in injured kidney, *J. Biol. Chem.* 279 (2004) 1968–1979.
- [24] L.E. Kelemen, The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? *Int. J. Cancer* 119 (2006) 243–250.
- [25] A. Pawlak, C. Toussaint, I. Levy, F. Bulle, M. Poyard, R. Barouki, G. Guellaen, Characterization of a large population of mRNAs from human testis, *Genomics* 26 (1995) 151–158.
- [26] N. van Baren, H. Chambost, A. Ferrant, L. Michaux, H. Ikeda, I. Millard, D. Olive, T. Boon, P.G. Coulie, PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells, *Br. J. Haematol.* 102 (1998) 1376–1379.
- [27] F. Wadelin, J. Fulton, P.A. McEwan, K.A. Spriggs, J. Emsley, D.M. Heery, Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia, *Mol. Cancer* 9 (2010) 226.
- [28] M.G. Field, C.L. Decatur, S. Kurtenbach, G. Gezgin, P.A. van der Velden, M.J. Jager, K.N. Kozak, J.W. Harbour, PRAME as an independent biomarker for metastasis in uveal melanoma, *Clin. Cancer Res.* 22 (2016) 1234–1242.
- [29] S.M. Pollack, Y. Li, M.J. Blaisdell, E.A. Farrar, J. Chou, B.L. Hoch, E.T. Loggers, E. Rodler, J.F. Eary, E.U. Conrad 3rd, R.L. Jones, C. Yee, NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycytidine, *PLoS One* 7 (2012) e32165.
- [30] P. Tan, C. Zou, B. Yong, J. Han, L. Zhang, Q. Su, J. Yin, J. Wang, G. Huang, T. Peng, J. Shen, Expression and prognostic relevance of PRAME in primary osteosarcoma, *Biochem. Biophys. Res. Commun.* 419 (2012) 801–808.
- [31] J.L. Pujol, T. De Pas, A. Rittmeyer, E. Vallieres, B. Kubisa, E. Levchenko, S. Wiesemann, G.A. Masters, R. Shen, S.A. Tjulandin, H.S. Hofmann, N. Vanhoutte, B. Salaun, M. Debois, S. Jarnjak, P.M. De Sousa Alves, J. Louahed, V.G. Brichard, F.F. Lehmann, Safety and immunogenicity of the PRAME cancer immunotherapeutic in patients with resected non-small cell lung cancer: a phase I dose escalation study, *J. Thorac. Oncol.* 11 (2016) 2208–2217.
- [32] R. Gutzmer, L. Rivoltini, E. Levchenko, A. Testori, J. Utikal, P.A. Ascierto, L. Demidov, J.J. Grob, R. Ridolfi, D. Schadendorf, P. Queirolo, A. Santoro, C. Loquai, B. Dreno, A. Hauschild, E. Schultz, T.P. Lesimple, N. Vanhoutte, B. Salaun, M. Gillet, S. Jarnjak, P.M. De Sousa Alves, J. Louahed, V.G. Brichard, F.F. Lehmann, Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study, *ESMO Open* 1 (2016) e000068.
- [33] D. Pankov, L. Sjöström, T. Kalidindi, S.G. Lee, K. Sjöström, R. Gardner, M.R. McDevitt, R. O'Reilly, D.L.J. Thorek, S.M. Larson, D. Veach, D. Ulmert, In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME), *Oncotarget* 8 (2017) 65917–65931.
- [34] W. Zhang, C.J. Barger, K.H. Eng, D. Klinkebiel, P.A. Link, A. Omilian, W. Bshara, K. Odunsi, A.R. Karpf, PRAME expression and promoter hypomethylation in epithelial ovarian cancer, *Oncotarget* 7 (2016) 45352–45369.

- [35] K. Partheen, K. Levan, L. Osterberg, G. Horvath, Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors, *Eur. J. Cancer* 42 (2006) 2846–2854.
- [36] K. Partheen, K. Levan, L. Osterberg, I. Claesson, G. Fallenius, K. Sundfeldt, G. Horvath, Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas, *Int. J. Cancer* 123 (2008) 2130–2137.
- [37] K. Partheen, K. Levan, L. Osterberg, I. Claesson, K. Sundfeldt, G. Horvath, External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas, *BMC Canc.* 9 (2009) 336.
- [38] I.G. Tkalia, L.I. Vorobyova, V.S. Svintsitsky, S.V. Nespryadko, I.V. Goncharuk, N.Y. Lukyanova, V.F. Chekhun, Clinical significance of hormonal receptor status of malignant ovarian tumors, *Exp. Oncol.* 36 (2014) 125–133.
- [39] L. Paleari, S. Gandini, N. Provinciali, M. Puntoni, N. Colombo, A. DeCensi, Clinical benefit and risk of death with endocrine therapy in ovarian cancer: a comprehensive review and meta-analysis, *Gynecol. Oncol.* 146 (2017) 504–513.
- [40] T.J. Herzog, B. Pothuri, Ovarian cancer: a focus on management of recurrent disease, *Nat. Clin. Pract. Oncol.* 3 (2006) 604.
- [41] S.L. Cooke, J.D. Brenton, Evolution of platinum resistance in high-grade serous ovarian cancer, *Lancet Oncol.* 12 (2011) 1169–1174.
- [42] R. Beckerman, C. Prives, Transcriptional regulation by p53, *Cold Spring Harb. Perspect Biol.* 2 (2010) a000935.
- [43] M. Eren, A.E. Boe, E.A. Klyachko, D.E. Vaughan, Role of plasminogen activator inhibitor-1 in senescence and aging, *Semin. Thromb. Hemost.* 40 (2014) 645–651.
- [44] D.R. Green, J.E. Chipuk, p53 and metabolism: inside the TIGAR, *Cell* 126 (2006) 30–32.